{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NYSE/APUS",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Apimeds Pharmaceuticals US, Inc., listed on the NYSE under ticker APUS. ISIN is not on the record, and the LEI is not on the record. Security type is Corporate. Segment is not on the record. Sector is 2834 Pharmaceutical Preparations. Jurisdiction is United States, Delaware. Listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 47 filings in the twelve months to 2026-11-08, across 37 filing days. Filings by type are: corporate news 11, director changes 8, directors' dealings 9, regulatory filings 12, results 4, ad hoc 1, halt or suspension 1, takeover 1. The median gap between filing days is 8.0 days. The latest filing is dated 2026-11-05, three days before the record date, and is of type directors' dealings. On the NYSE, 3256 issuers have a median cadence gap of 6.0 days, a median of 64.0 filings and a median latency of 4.0 days. In the sector 2834 Pharmaceutical Preparations, 526 issuers have a median cadence gap of 6.0 days, a median of 63.0 filings and a median latency of 4.0 days. The issuer's cadence gap is above both medians. Its filing count is below both medians. Its latency is below both medians.\n\n## Auditor\n\nThe auditor of record is Kreit & Chiu CPA LLP, located in New York, New York. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. Domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations pages.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe issuer is sealed for the years 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://data.sec.gov/submissions/CIK0001894525.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NYSE/APUS (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NYSE/APUS (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm",
    "state": "sourced",
    "value": "Kreit & Chiu CPA LLP"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm",
    "state": "sourced",
    "value": "6651"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm",
    "state": "sourced",
    "value": "New York, New York"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NYSE/APUS",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 3256,
     "median_cadence_gap_days": 6,
     "median_filings": 64,
     "median_latency_days": 4,
     "name": "NYSE"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 1,
    "corporate_news": 11,
    "director_change": 8,
    "directors_dealings": 9,
    "halt_suspension": 1,
    "regulatory_filing": 12,
    "results": 4,
    "takeover": 1
   },
   "cadence_median_gap_days": 8,
   "filing_days": 37,
   "filings": 47,
   "latency_days": 3,
   "latest": [
    {
     "category": "3",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1894525/000216354726000001/xslF345X06/primary_doc.xml",
     "title": "3 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-11-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1894525/000209946326000001/xslF345X06/primary_doc.xml",
     "title": "3 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "3",
     "date": "2026-11-02",
     "source": "https://www.sec.gov/Archives/edgar/data/1894525/000209036426000001/xslF345X06/primary_doc.xml",
     "title": "3 — PRIMARY DOCUMENT",
     "type": "directors_dealings"
    },
    {
     "category": "8-K",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026108780/ea0308250-8k_apimeds.htm",
     "title": "8-K — CURRENT REPORT (items 8.01,9.01)",
     "type": "corporate_news"
    },
    {
     "category": "8-K",
     "date": "2026-10-01",
     "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026105484/ea0307269-8k_apimeds.htm",
     "title": "8-K — CURRENT REPORT (items 5.02,9.01)",
     "type": "director_change"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/APUS",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NYSE"
   },
   "isin": {
    "market": "US",
    "reason": "no LEI, so no GLEIF ISIN route; EDGAR carries no ISIN",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001894525.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001894525.json",
    "state": "sourced",
    "value": "Apimeds Pharmaceuticals US, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001894525.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001894525.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "APUS"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:6edd32c80785f4ef9ecab07c84cd4da70d04b5e60f2bf0648324e828b727f4cc",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NYSE/APUS",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:6edd32c80785f4ef9ecab07c84cd4da70d04b5e60f2bf0648324e828b727f4cc",
 "path": "/us/NYSE/APUS",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Apimeds Pharmaceuticals US, Inc., listed on the NYSE under ticker APUS. ISIN is not on the record, and the LEI is not on the record. Security type is Corporate. Segment is not on the record. Sector is 2834 Pharmaceutical Preparations. Jurisdiction is United States, Delaware. Listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 47 filings in the twelve months to 2026-11-08, across 37 filing days. Filings by type are: corporate news 11, director changes 8, directors' dealings 9, regulatory filings 12, results 4, ad hoc 1, halt or suspension 1, takeover 1. The median gap between filing days is 8.0 days. The latest filing is dated 2026-11-05, three days before the record date, and is of type directors' dealings. On the NYSE, 3256 issuers have a median cadence gap of 6.0 days, a median of 64.0 filings and a median latency of 4.0 days. In the sector 2834 Pharmaceutical Preparations, 526 issuers have a median cadence gap of 6.0 days, a median of 63.0 filings and a median latency of 4.0 days. The issuer's cadence gap is above both medians. Its filing count is below both medians. Its latency is below both medians.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Kreit & Chiu CPA LLP, located in New York, New York. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. Domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. Segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations pages.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The issuer is sealed for the years 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0001894525.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NYSE/APUS"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/1894525/000121390026051139/ea0288344-10k_apimeds.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NYSE/APUS"
  }
 ],
 "title": "Apimeds Pharmaceuticals US, Inc. (APUS) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}